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Background: The effectiveness of sulphadoxine-pyrimethamine (SP) intermittent preventive treatment of malaria
in pregnancy (IPTp) might be compromised by high prevalence of resistance-associated Plasmodium falciparum
dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutations. As a proxy for IPTp-SP effectiveness,
the in vivo efficacy of SP to clear parasitaemia and prevent reinfection in asymptomatic parasitaemic pregnant
women in an area with high SP resistance prevalence was assessed.
Methods: Pregnant women 16–26 weeks’ gestation with asymptomatic parasitaemia presenting for antenatal
care were given IPTp-SP and followed for 42 days. The primary outcome was polymerase chain reaction (PCR)
uncorrected 42-day survival rate; the per cent of patients without recrudescence or reinfection by day 42. PCR was
used to distinguish recrudescence from reinfection. DNA was sequenced to detect resistance-associated dhfr and
dhps mutations.
Results: Of 245 pregnant women included in the intention-to-treat analysis, 93.9% cleared their parasitaemia by
day 7. The day 42 PCR-uncorrected survival rate was 58.1% (95% confidence interval (CI) 51.5-65.7) and day 42
PCR-corrected survival was 68.7% (CI 61.4-76.0). Recrudescence was more common among primi- than among
multigravid women; recrudescence rate 33.3% (CI 25.1-42.4%) versus 21.4% (CI 15.0-29.0%) (log rank test p-value
0.006). The quintuple mutant was present in nearly all samples (95%), while 2% were sextuple mutants with an
additional mutation at dhps A581G.
Conclusions: SP efficacy for acute malaria treatment has been compromised by resistance, but SP retains partial
activity among pregnant women with asymptomatic parasitaemia, and thus might be useful for IPTp. Nonetheless,
research on non-SP IPTp regimens should continue.
Trial registration: ClinicalTrials.gov NCT01120145.
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Malaria in pregnancy is associated with severe maternal
anaemia, placental malaria, low birth weight (LBW),
maternal mortality, and infant morbidity and mortality,
particularly among primigravid women [1]. Intermittent
preventive treatment with sulphadoxine-pyrimethamine
(IPTp-SP) reduces the adverse consequences of malaria* Correspondence: jgutman@cdc.gov
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unless otherwise stated.among pregnant women, including third-trimester mater-
nal anaemia, placental parasitaemia, and the prevalence of
LBW infants [2-4]. When this study was conducted, the
policy in Malawi was to give SP at the first antenatal care
(ANC) visit after quickening (about 20 weeks) and again
during the third trimester, with a total of two doses during
pregnancy; this has since been updated in line with re-
vised WHO recommendations to provide IPTp-SP at each
scheduled ANC visit starting early second trimester with a
minimum of three doses during pregnancy [5].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mulation of single nucleotide polymorphisms (SNPs)
that encode amino acid substitutions in the Plasmodium
falciparum dihydropteroate synthase (dhps) and dihy-
drofolate reductase (dhfr) genes; the quintuple mutant
haplotype (dhfr mutations N51I, C59R, S108N, and dhps
mutations A437G and K540E), which is associated with
failure of SP in in vivo studies in children, has been fixed
in Malawi since 2005 [6,7]. Due to the high level of SP
resistance, SP has not been recommended for treatment
of symptomatic malaria in Malawi since 2007. Nonethe-
less, studies suggest that SP remains effective as IPTp
even when it is no longer effective as a treatment in
symptomatic children [2,8]. However, studies from both
Tanzania and Malawi suggest IPTp-SP effectiveness
could be compromised by the presence of additional
mutations conferring increased resistance to SP [9-11];
in particular, the presence of an additional mutation at
dhps A581G (the sextuple mutant) seems to significantly
compromise the effectiveness of IPTp-SP [10,12,13].
As resistance to SP increases, it is important to moni-
tor the efficacy of IPTp-SP to determine when this inter-
vention no longer provides any benefit. However, there
is no standardized methodology for monitoring. In vivo
efficacy in children does not correlate well with the
degree of protection afforded to pregnant women [2],
because pregnant women have partial immunity, and
thus other methods to monitor IPTp-SP effectiveness
are needed. As a proxy for SP effectiveness, a 42-day
in vivo efficacy study was conducted among asymp-
tomatic pregnant women to assess the efficacy of SP
for clearing existing parasitaemia and preventing new
infection. As pregnancy specific anti-parasitic immunity
increases with each pregnancy, efficacy was assessed sep-
arately among primigravid and multigravid women.
Methods
Study site
The study was conducted in the antenatal clinic of
Machinga District Hospital, Malawi from March 2010 to
January 2011. Residents are mainly of the Yao ethnic group,
who earn their living through subsistence farming, fishing
and small businesses. Machinga District Hospital is the
primary hospital for a catchment area including 369,614
people, with approximately 5,712 deliveries per year. In
2011, there were 57,999 clinically diagnosed malaria cases,
of which 29,626 (51%) were aged ≥ five years [12]. Malaria
transmission in the district is stable throughout the year
with a peak in the rainy season, from December to March.
Parasite prevalence was 42.3% in children aged < five years
in the Southern Region in the most recent malaria indi-
cator survey [12]. The vast majority of malaria infections
are caused by Plasmodium falciparum. Resistance to SP is
widespread; the quintuple mutation is fixed, although atthe time of this study the dhfr I164L mutation had not
been detected and the dhps A581G mutation was detected
at extremely low frequency (<1%) [6].
Sample size
Parasitologic failure rate among pregnant women treated
with SP was 11% in 2004, double the failure rate in 1996
(5%) [14]. Allowing for the possibility that failure rates
had increased, a sample size of 300 women was deter-
mined to be sufficient to estimate the proportion of fail-
ures with a 95% confidence interval (CI) width of 0.10,
assuming a 20% failure rate, and allowing for approxi-
mately 20% loss to follow-up [15].
Enrolment and follow-up
Pregnant women of all parities presenting to Machinga
District Hospital for ANC visits were eligible for inclu-
sion if they: 1) were between 16 and 26 weeks’ gestation
(based on last menstrual period (LMP) or quickening);
2) were eligible to take SP on the day of enrolment; 3)
had malaria parasitaemia of any density; 4) had an axil-
lary temperature below 37.5°C; 5) had a viable foetus
documented by detection of a foetal heartbeat or foetal
movement; 6) were HIV-negative; 7) had not received
any anti-malarials or antibiotics with anti-malarial activity
in the previous month; 8) had no history of SP hypersensi-
tivity; and, 9) provided informed consent for participation.
At enrolment, a finger-prick blood specimen was collected
for malaria rapid diagnostic test (RDT) (Paracheck-Pf
Device (Orchid Biomedical Systems, India)), malaria mi-
croscopy, haemoglobin measurement (HemoCue 201,
HemoCue AB, Sweden), and dried blood spot (DBS) for
polymerase chain reaction (PCR); three tablets of SP
(a total of 1,500 mg sulphadoxine and 75 mg of pyri-
methamine) was administered by directly observed ther-
apy. Quality-assured SP was procured from Durbin Plc,
Middlesex, UK.
Following enrolment, patients were assessed weekly
until day 42 or until they developed parasitaemia. At each
visit, women were assessed for fever (axillary tempe-
rature ≥37.5°C) or histoy of fever and medication use,
and a finger-prick blood specimen was collected for
thick smear, haemoglobin measurement, and DBS for
PCR to distinguish reinfection from recrudescence.
Thick blood smears were prepared with Field’s stain
and the number of parasites per 200 white blood cells
(WBC) counted. Blood smears were considered negative if
no parasites were found after counting 1000 WBC. Blood
smears were read by two independent microscopists with
a third read in the case of discordant results (discrepancy
between positivity/negativity or greater than 50% differ-
ence in parasite counts). Parasite density was calculated
as the average of the closest two readings, assuming
an average WBC count of 8,000/mm3. Participants were
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sick. Women with positive blood smears at any time on or
after day 4 were treated with artemether-lumefantrine per
national guidelines.
Molecular analyses
Resistance to SP was measured by direct sequencing of
DNA extracted from DBSs collected from the day of
enrolment. The DNA samples were sequenced at dhfr
codons 51, 59, 108, 164 and dhps codons 436, 437, 540,
581, 613 using a standard protocol [16]. The quintuple
mutant was defined as an isolate containing dhfr muta-
tions N51I, C59R and S108N, and dhps mutations
A437G and K540E [17]. The presence of an additional
mutation at dhps A581G defined the sextuple mutant.
In order to differentiate recrudescence from reinfec-
tion, DNA samples extracted from paired DBS samples
from enrolment (day 0) and day of failure were assessed
using WHO-recommended PCR procedures for testing
polymorphisms at the genes encoding merozoite surface
protein 1 (msp-1) and msp-2 [18].
Statistical analysis
As IPTp-SP is designed to both treat prevalent parasit-
aemia as well as prevent incident parasitaemia, the main
outcome of interest was clearance of parasites without
recrudescence or reinfection in the 42 days following SP
administration (survival), which differs from the stand-
ard WHO in vivo, in which the main outcome of interest
is clearance of parasites without recrudescence (i.e. treat
prevalent infection only) [15]. Data analysis was done in
SAS version 9.3 (Cary, NC, USA) and R version 3.0.1
(Vienna, Austria). Survival curves were calculated using
the Kaplan-Meier method; in absence of failure, women
were censored on the last day for which data were avail-
able [19]. The log-rank test was used to assess for sig-
nificant differences between curves. Multiple imputation
(with 10 imputed datasets) was used to assess the sensi-
tivity of results when incorporating cases where PCR
testing for recrudescence versus reinfection was unsuc-
cessful [20]. Cox proportional hazards regression was
used to test for predictors of failure [21]. The final, mul-
tivariable model was chosen to reflect predictors which
improve the fit of the model based on Schwarz’s Bayesian
Information Criterion [22]. For all analyses, a p-value
of <0.05 considered significant. Plots were generated with
the ggplot2 package [23].
Ethics
The study was approved by the ethical review boards of
the University of Malawi College of Medicine (Blantyre,
Malawi) and the Centers for Disease Control and Pre-
vention (Atlanta, GA, USA). Written informed consent
was obtained from all participating women prior toenrolment. The study was registered at ClinicalTrials.
gov (NCT01120145).Results
A total of 2,566 women were screened; P. falciparum
antigenaemia was detected by RDT in 759 (29.6%). Of
the 301 women who met all inclusion criteria and con-
sented to enrolment, 299 were enrolled; 58 women were
lost prior to the first follow-up, and were excluded from
the analysis. A total of 245 pregnant women were in-
cluded in the analyses (Figure 1). Of these, 114 (46.5%)
were primigravid (G1) and 131 (53.5%) were multigravid
(G2+) (Table 1). The mean age was 21.7 years (range
14–42) overall, 18.8 years (range 14–38) among primi-
gravid women and 24.3 years (range 16–42) among mul-
tigravid women; 54.3% were less than or equal to
20 years old. In all, 32.2% reported having used a bed
net on the night prior to enrolment; 84.8% of these were
insecticide-treated nets (ITNs). Bed net use was higher
among multigravid than among primigravid women
(41.2 versus 21.9%, p = 0.001). The mean gestational age
at enrolment was 21 weeks (IQR 18–24); multigravid
women were enrolled on average 1.5 weeks later in ges-
tation than primigravid women (p = 0.002).Recrudescence and reinfection
During the course of the study, 63 women (25.7%)
remained aparasitaemic through day 42 while 87 women
developed parasitaemia (35.5%) of whom 51 (58%) had
recrudescent infection, 17 (20%) were reinfected, and in
19 (22%) PCR was unavailable (13 samples could not be
amplified and six were unavailable). Reinfection occurred
at a median of 15 days (interquartile range 14 – 28 days).
A total of 95 women were censored prior to reaching a
valid study end point; 43 women were lost to follow-up,
and another 52 women were withdrawn due to protocol
violation (46 were given IPTp-SP at day 35 and six re-
ceived anti-malarial treatment without evidence of malaria
or another antibiotic with anti-malarial activity).
Overall, 93.9% of women cleared their infection by day
7; the PCR-uncorrected 28-day survival rate was 67.5%
(Table 2). The PCR-uncorrected 42-day survival rate was
58.1%; the survival rate was 45.8% in primigravid women
and 68.0% in multigravid women. Over 42 days, there
was a significant association between survival and gravid-
ity (log-rank Chi-sq = 11.5, df = 1, p = 0.0007) (Figure 2).
PCR-corrected survival, including multiple imputations
for missing PCR results, was 76.4% (CI 70.2-82.6) at day
28 and 68.7% (CI 61.4-76.0) at day 42. Recrudescence was
more common among primi- than among multigravid
women, with a recrudescence rate of 44.0% (CI 31.6-
56.3%) and 23.6% (CI 14.9-32.3%), respectively (log-rank
Chi-sq = 9.3, df = 1, p = 0.002) by day 42.
Figure 1 Enrolment flow diagram for sulphadoxine-pyrimethamine (SP) modified in vivo efficacy study in pregnant women*. *Study included
pregnant women with asymptomatic malaria parasitaemia attending antenatal care for their first dose of intermittent preventive treatment in
pregnancy with SP (IPTp-SP), Machinga District Hospital, Malawi 2009–2010. RDT = rapid diagnostic test.
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protective against developing recrudescence or reinfection
in univariate modelling, however, in the multivariate
model, only gravidity remained significant (Table 3). When
examining the risk of recrudescence only, as expected, bed
net use was no longer a significant factor, and only gravid-
ity remained significant in both univariate and multivariate
analyses.
Haematologic response
Mean haemoglobin increased by 0.3 mg/dL (95% CI 0.1-
0.4, p = 0.0001) from day 0 until the last day of follow-
up. The change was greater among primigravid women
(0.4 mg/dL (95% CI 0.2-0.7) than among multigravid
women (0.1 mg/dL (95% CI −0.05- 0.3), p = 0.02). A sig-
nificant interaction was found between day of follow-upand gravid class (F(6,243) = 3.86, p = 0.0011) indicating the
change in haemoglobin levels during the study was not
the same in each group. Figure 3 shows the raw means
with 95% confidence intervals across the two groups.
Molecular markers of SP resistance
Of the 245 day 0 samples, a variable number could be
amplified at each codon. Where samples were amplified,
there was a very high frequency of mutation (≥97%) at
each of the following codons: dhfr-51, dhfr-59, dhfr-108,
dhps-437, and dhps-540 (Table 4). Of 182 samples that
were successfully genotyped at all five codons, 95% carried
the quintuple mutant. Four samples (2%) (one from a pri-
migravid woman and three from multigravid women), all
of which carried the quintuple mutation, were mutated at
dhps-581 indicating the presence of sextuple mutants.
Table 1 Baseline characteristics of asymptomatic parasitaemic pregnant women enrolled in a modified in vivo efficacy
study of sulphadoxine-pyrimethamine (SP), stratified by gravidity
Total (N = 245) Primigravid (N = 114) Multigravid (N = 131) p-value
Age, mean (SD) 21.7 (5.0) 18.8 (2.9) 24.3 (5.0) <0.0001
Age ≤20 years 54.3% 87.7% 25.2% <0.0001
Bed net use
Used a bed net last night 32.2% 21.9% 41.2% 0.001
Used an insecticide-treated bed net last night 27.3% 14.9% 38.2% <0.0001
Maternal weight (kg), mean (SD) 55.8 (7.1) 55.4 (6.9) 56.1 (7.3) 0.40
Education (years), mean (SD) 6.2 (3.0) 6.9 (2.9) 5.6 (3.0) <0.001
Perceived below average wealth status 78.0% 81.6% 74.6% 0.19
Gestational age at enrolment (weeks), mean (SD) 21.0 (3.9) 20.2 (3.6) 21.8 (4.0) 0.002
Haemoglobin at enrolment, mean (SD) 9.8 (1.3) 9.2 (1.1) 10.4 (1.3) <0.0001
Per cent of women with anaemia (Hb <11 g/dL) at enrolment 81.2% 96.5% 67.9% <0.0001
Per cent of women with gametocytaemia 0.4% 0.00% 0.8% -
Parasite density (parasites/ml), geometric mean (range) 273 (32–12,835) 372 (48–12,835) 209 (32–8,955) <0.0001
SD = standard deviation, Hb = haemoglobin.
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logic response (ACPR), two had a treatment failure (one
on day 7 and the other on day 8), and one was censored
on day 35 due to a protocol violation. The presence of the
sextuple mutant was detected in three additional samples
from the day of failure (one from a primigravid woman
and two from multigravid women). Unfortunately, the
day-of-failure samples from the two patients who had sex-
tuple mutants detected at baseline and subsequently failed
therapy could not be amplified at codon dhps-581.
Discussion
Overall, 58.1% of pregnant women who presented with
asymptomatic parasitaemia and received SP on day 0Table 2 Polymerase chain reaction survival rates by week am
sulphadoxine-pyrimethamine at day 0, stratified by gravidity
Uncorrected
Day of follow-up Primigravid survival rate (95% CI) Mu
7 92.1% (87.3-97.2) 95.4
14 76.5% (68.8-85.0) 88.3
28 58.5% (49.6-69.1) 75.0
35 48.6% (39.3-60.0) 71.2
42 45.8% (36.1-58.2) 68.0
Corrected
Day of follow-up Primigravid survival rate (95% CI) Mu
7 95.9% (91.0, 100.0) 97.1
14 84.2% (76.5, 91.9) 91.4
28 68.3% (58.3, 78.3) 82.8
35 59.3% (48.1, 70.5) 78.6
42 56.0% (43.7, 68.3) 76.4
CI: confidence interval.remained aparasitaemic for 42 days, in an area with a
high prevalence of SP resistance (95% carried the quintu-
ple mutant, 2% carried the sextuple mutant at baseline).
Parasite-free survival rates were higher among multigravid
(68%) than among primigravid (46%) women. Although
28-day survival was 67.5%, well below the 90% WHO
threshold for changing the recommendation for first-line
treatment of uncomplicated malaria [24], this study sug-
gests that SP retains some efficacy among pregnant
women, and that monthly dosing of IPTp-SP, as recom-
mended by WHO [25], likely continues to provide benefit.
This is supported by a recent study conducted at the same
site assessing the effect of IPTp-SP on birth outcomes,
which found a dose-dependent protective effect of IPTp-ong asymptomatic parasitaemic women treated with
ltigravid survival rate (95% CI) Overall survival rate (95% CI)
% (91.9-99.1) 93.9% (90.9-96.9)
% (82.9-94.0) 82.9% (78.2-87.9)
% (67.6-83.2) 67.5% (61.6-74.0)
% (63.4-79.9) 61.1% (54.8-68.1)
% (59.5-77.6) 58.1% (51.5-65.7)
ltigravid survival rate (95% CI) Overall survival rate (95% CI)
% (93.9, 100.0) 96.5% (93.6, 99.4)
% (86.2, 96.7) 88.2% (83.6, 92.8)
% (75.5, 90.1) 76.4% (70.2, 82.6)
% (70.6, 86.6) 70.2% (63.5, 77.0)
% (67.7, 85.0) 68.7% (61.4, 76.0)
Figure 2 Kaplan-Meier survival curve estimates for asymptomatic
parasitaemic women following treatment with sulphadoxine-
pyrimethamine at day 0 with 95% confidence intervals, by gravidity.
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come of LBW, preterm delivery, and small for gestational
age (SGA) [26]. Similarly, a recent meta-analysis found a
greater benefit of IPTp-SP when three or more doses were
given during pregnancy compared to two, irrespective of
the prevalence of the quintuple mutation [8].
Although the presence of the quintuple mutant pre-
dicts failure of SP treatment among children aged < five
years with acute malaria [17], IPTp-SP remains effective
even where the quintuple mutant is highly prevalent [8].Table 3 Factors associated with treatment failure among asym




Treatment failure, uncorrected by PCR
ITN use last night (reference: no ITN use last night) 0.54 0.32
Age: comparing >20 years to ≤20 years 0.68 0.44
Schooling years (continuous) 1.01 0.94
Log parasite density (continuous) 0.96 0.79
Gravidity: comparing multigravid to primigravid 0.48 0.31
Treatment failure, corrected by PCR
ITN use last night (reference: no ITN use last night) 0.54 0.27
Age: comparing >20 years to ≤20 years 0.62 0.35
Schooling years (continuous) 1.05 0.95
Log parasite density (continuous) 0.97 0.75
Gravidity: comparing multigravid to primigravid 0.41 0.23
HR = hazard ratio, CI = confidence interval, ITN = insecticide-treated bed net, PCR = pIn this study, due to the extremely high prevalence of
the quintuple mutant, it was not possible to assess
whether this haplotype was associated with a higher rate
of failure; despite the high prevalence of the quintuple
mutant, IPTp-SP continues to improve birth outcomes
in this area [26]. In Tororo, Uganda, where >90% of par-
asites carry the quintuple mutant, Arinatwe et al. also
found a significant reduction in a composite adverse
outcome measure composed of placental malaria, LBW,
maternal parasitaemia, or maternal anaemia [27]. A
study assessing SP in vivo efficacy among asymptomatic,
parasitaemic pregnant women in Zambia, where the
quintuple mutant was present in 61% of samples at base-
line, found no association of the quintuple mutant with
treatment failure [28]. In that study setting, IPTp-SP was
associated with a dose-dependent reduction in LBW,
with a greater impact among primi- and secundigravid
compared to multigravid women [29].
Although IPTp-SP remains effective even in the pres-
ence of the quintuple mutant, several studies suggest
that the presence of the sextuple mutant is associated
with decreased effectiveness of IPTp-SP, as evidenced by
either increased parasite densities, increased placental
inflammation, or decreased birth weight among children
born to women infected with parasites carrying the sex-
tuple mutant [10,12,13]. In an area with extremely high
levels of resistance in Muheza, Tanzania, where the
quintuple mutant is fixed and the mean fraction of re-
sistant alleles at dhps 581 was 0.31, IPTp-SP was not
associated with a statistically significant benefit at the
population level [11]. The lack of efficacy may reflect the
effect of the high prevalence of the sextuple mutant or
alternatively may have been due to insufficient power inptomatic parasitaemic women treated with
Multivariable
I 95% CI
Upper p-value HR Lower Upper p-value




0.74 <0.001 0.53 0.34 0.83 0.006




0.73 0.002 0.45 0.25 0.82 0.009
olymerase chain reaction.
Figure 3 Mean haemoglobin levels with 95% confidence intervals
broken down by gravidity.
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favour IPTp. As the prevelance of SP resistance con-
tinues to increase, additional studies are needed to assess
the true effect of the sextuple mutant on IPTp-SP effi-
cacy, and the prevalence at which a population level ef-
fect is seen.
The protective effect of IPTp-SP is thought to be a re-
sult of both the ability to clear existing infections as well
as to prevent new infections. Some have argued that
the prophylactic effect is of primary importance [30].Table 4 Prevalence of mutations Plasmodium falciparum
dihydrofolate reductase (dhfr) and dihydropteroate
synthase (dhps) mutations associated with resistance to
sulphadoxine-pyrimethamine detected at day 0
Mutation Mutant (n)/Total (N) Per cent mutant
dhfr N51I 209/212 99%
dhfr C59R 210/214 98%
dhfr S108N 211/214 99%
dhfr I164L 2/211 1%
dhps A437G 219/225 97%
dhps K540E 201/204 99%
dhps A581G 4/204 2%




*Double mutant = Pfdhps mutations A437G and G540E; Triple mutant = Pfdhfr
mutations N51I, C59R and S108N; Quintuple mutant = Pfdhfr mutations N51I,
C59R, S108N and Pfdhps mutations A437G and K540E.However, a recent study from Malawi found that IPTp-SP
was more effective in clearing existing sub-microscopic in-
fections than preventing new sub-microscopic infections
[31]. Moreover, intermittent screening with a RDT and
treatment only of parasitaemic women has been shown to
have similar benefits to IPTp-SP in preventing LBW and
severe maternal anaemia, even when using a treatment
with a short-acting drug such as artesunate-amodiaquine
or artemether-lumefantrine [32]. (Tagbor et al., A non-
inferiority, individually randomized trial of intermittent
screening and treatment versus intermittent preventive
treatment in the control of malaria in pregnancy, submit-
ted). This suggests that the treatment effect might be
more important than the prophylactic effect. In this study,
only 6.1% of women had persistent infection on day 7,
indicating that the vast majority of infections were sup-
pressed, despite the high prevalence of parasite resistance
to SP. SP was effective at clearing infections likely due to
the fact that the infections were of low density; however
immunity also played a role given the differential rate of
cure between primi- and multigravid women.
Across the reported in vivo efficacy studies among
pregnant women, there appears to be a correlation
between failure rate and the prevalence of SP resistance
mutations (Desai M, et al.: Impact of sulfadoxine-
pyrimethamine resistance on effectiveness of intermittent
preventive therapy for malaria in pregnancy at clearing in-
fections and preventing low birth weight: A prospective,
multi-country observational study across Africa, submit-
ted). In a recent study in Mali and Burkina Faso, where
the triple dhfr mutant was detected in <50% and the dhps
K540E mutation was detected in less than 1% of samples,
the overall PCR uncorrected failure rate was 4.9% [33]. In
Benin, where the dhfr/dhps quadruple mutant was de-
tected in >80% of parasite isolates, but dhps K540E was
not detected, 11% of women with positive smear at the
time of IPTp-SP administration had parasites detected by
microscopy on follow-up within one month [34]. In
Zambia, where the dhfr/dhps quintuple mutant was de-
tected in parasites in 63% of women, failure rates were
26% by 35 days, [28] while in this site in Malawi, where
parasites from 95% of women carried the quintuple mu-
tant, failure rates were 32.5% at 28 days and 38.9% by day
35. While failure rates in these modified in vivo efficacy
studies appear to correlate quite well with the prevalence
of SP resistance mutations, there is poor correlation be-
tween SP resistance and IPTp-SP efficacy; the effect of
IPTp-SP on infant birth weight or maternal haemoglobin
remains remarkably constant over the spectrum of resist-
ance, up to fixation of the quintuple mutant (Desai M,
et al.: Impact of sulfadoxine-pyrimethamine resistance on
effectiveness of intermittent preventive therapy for malaria
in pregnancy at clearing infections and preventing low
birth weight: A prospective, multi-country observational
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suggest that the additional mutation at dhps A580G ren-
ders IPTp-SP ineffective, however, additional studies are
needed to confirm this relationship. Given the expense
and difficulties associated with conducting in vivo efficacy
studies, and the correlation of failure rates with SP resist-
ance mutations, consideration should be given to moni-
toring SP resistance markers instead of conducting in vivo
efficacy studies. However, until a clearer relationship exists
between the prevalence of molecular markers of SP resist-
ance and the threshold at which IPTp-SP is no longer
effective, IPTp-SP should continue to be delivered, ideally
at each scheduled ANC visit, with close monitoring in
areas where the sextuple mutant is emerging.
Limitations
Although this study suggests a beneficial effect of SP, the
lack of a placebo arm impedes the ability to assess the
true effect of SP treatment. It is possible that some
women, particularly the multigravid ones, would have
been able to clear the infections from their peripheral
blood even without being treated with SP. However,
until there is more evidence that IPTp-SP does not pro-
vide any benefit, it is not ethical to conduct such a study.
Furthermore, as these women were not followed until
delivery, it is not known whether the infections were
cleared from the placenta, which remains a relatively
protected site for malaria.
Conclusion
Despite fixation of the quintuple mutant in this popu-
lation, SP retained some benefit when administered to
asymptomatic parasitaemic pregnant women. The differ-
ence in parasite clearance in multigravid versus primigra-
vid women highlights the importance of pre-existing
immunity in clearing parasites. Although the prevalence
of SP resistance has compromised the efficacy of SP as a
treatment for acute malaria, it retains partial activity
among pregnant women with asymptomatic parasitaemia,
and is still useful when given as IPTp. Nonetheless, it
remains important to continue to search for alternative
regimens to prevent malaria in pregnancy.
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